Navigation Links
Gladstone scientists uncover potential mechanism of memory loss in Alzheimer's disease
Date:9/5/2007

SAN FRANCISCO, CA -- September 6, 2007 -- Researchers at the Gladstone Institute of Neurological Disease (GIND) and Baylor College of Medicine have discovered a mechanism by which the protein Amyloid-beta(AB) may impair neurological functions in Alzheimer's disease. AB, which is known to accumulate in the brains of Alzheimer patients, has long been a focus of research into the causes and treatment of the disease. In a study published in the journal Neuron, Gladstone scientists found that A-beta triggers abnormal overexcitation of the very brain networks that are responsible for learning and memory.

"Such abnormal network activity in Alzheimer's patients was thought to be a collateral or secondary event caused by the degeneration of nerve cells," said Jorge J Palop, PhD, Gladstone research scientist and lead author of the study. "But our study suggests that this activity may actually be a primary effect of A-beta and an early determinant of cognitive failure."

The Gladstone team used several genetically engineered mouse models of AD in which memory deficits are triggered by a human gene that causes high levels of A-beta. They discovered that high levels of A-beta induce an insidious type of seizure activity in learning and memory centers that is not accompanied by the usual twitching and jerking movements seen in many forms of epilepsy. In fact, it took sophisticated brain wave recordings in freely behaving mice by electroencephalography (EEG) and telemetry to detect the seizure activity.

"We were really surprised by these findings because A-beta had previously been suspected to primarily suppress neuronal activity," said Lennart Mucke, MD, GIND director and professor of neurology and neuroscience at the University of California, San Francisco (UCSF), and senior author of the study. "This abnormal brain activity could play an important role in the development of Alzheimer-related cognitive impairments."

Physicians have long recognized that Alzheimer patients have a higher incidence of convulsive seizures than reference populations. The new study indicates that A-beta is to blame for this problem and raises the disconcerting possibility that these patients may also have non-convulsive seizures that could easily escape detection by standard clinical exams. The investigators are eager to test this hypothesis in a planned follow-up study of human subjects.

"Our results have important therapeutic implications, because the prevention and reversal of non-convulsive seizure activity has not yet been a major focus of clinical trials in Alzheimer's disease. Our results suggest that the suppression of this activity might prevent and possibly even reverse cognitive impairments induced by high levels of A-beta," said Dr. Mucke.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. Scientists find way to make human collagen in lab
3. Wisconsin scientists to be recognized for innovative biofuel technology
4. UW-Madison scientists to mimic nature for newest cancer drugs
5. UW scientists study strange material with communications potential
6. Scientists find nanotech method for examining cells
7. UW space scientists use Keck telescope to study wild weather of Uranus
8. UW computer scientists tout achievements and explain industry shortcomings
9. Facing shortage of U.S. scientists, UW wants to boost math enrollment
10. UW-Madison scientists find a key to cell division
11. TIP/UW Scientists Provide Mars Rover Commentary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
Breaking Biology News(10 mins):